

November 9, 2017

## **ONO announces collaboration with Neurimmune in Neurodegenerative Diseases Field**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director and CEO, Gyo Sagara; “ONO”) announced today that it entered into a collaboration agreement with Neurimmune Holding AG (Zurich, Switzerland; Chief Operating Officer & General Manager, Michael Salzmann, PhD; Neurimmune) focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases.

Under the terms of the collaboration agreement Neurimmune will conduct research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine™ (RTM™) technology platform. Ono will be exclusively responsible for worldwide development and marketing of products. Neurimmune will receive an upfront payment, research fees, success-based milestones on the research and development progress, as well as royalties on product sales.

“Ono identified Neurimmune as the partner of choice for the generation of leads for a target in our portfolio,” said Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of ONO. “We are excited to work with Neurimmune on identifying and developing the next generation of innovative treatments in neurodegenerative disease area.”

“We are excited to partner with Ono, a global pioneer of innovative medicines.”, said Jan Grimm, Chief Scientific Officer and co-founder of Neurimmune. “This new collaboration serves our commitment to patients to fully leverage our RTM™ technology for the discovery and development of breakthrough medicines in areas of high unmet medical need.”

### **About Neurimmune**

Neurimmune is a biopharmaceutical company dedicated to the development of unique classes of human therapeutic antibodies for the treatment and prevention of important human diseases with a high unmet medical need. Established in 2006 as a spin-off of the University of Zurich, Switzerland, Neurimmune has rapidly grown into a leader in the field of recombinant human monoclonal antibody therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab for Alzheimer’s disease was partnered with Biogen and is currently in phase 3 clinical trials. BIIB054 for Parkinson’s and BIIB076 for Alzheimer’s were acquired by Biogen and are in phase 1.

### **About Neurimmune's Reverse Translational Medicine™ (RTM™) Technology Platform**

Reverse Translational Medicine™ (RTM™) is Neurimmune's proprietary technology platform. It is based on the scientific understanding and high-throughput analyses of human immune responses to disease-related proteins in selected populations including elderly with the capability to stay healthy during the aging process. Neurimmune's recombinant human monoclonal antibody therapeutics combine the full complement of advantages provided by human affinity maturation and tolerance selection. These processes are biologically optimized through evolutionary processes over millions of years providing unsurpassed efficacy and safety in human subjects. Neurimmune's molecular engineering technology preserves favorable immunobiological features of human-derived antibodies creating an entirely novel generation of highly optimized biopharmaceutical drugs. With their superior biophysical, pharmacological and safety properties, Neurimmune's therapeutic antibodies combine first-in-class with best-in-class potential.

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

[public\\_relations@ono.co.jp](mailto:public_relations@ono.co.jp)